After 20+ years of research & development in the Boston/Cambridge biotech sector, Ruud Hulspas founded Cellular Technologies Bioconsulting, LLC in 2016 with the intend to contribute to successful commercialization of cell therapy through a focus on rigor and reproducibility in cell processing and analytical assays. Offices are located in the USA and in the Netherlands.
Ruud has over 25 years of experience in assay development, cell characterization and cell selection by flow cytometry. His expertise is used to tackle the challenges in QA/QC and CMC for commercial cell therapy.
Our vision is to deliver standards for reliable cell product characterization and disease monitoring in cell therapy. Our mission is to make significant contributions to the development of reliable, sustainable analytical and cell selection methods.